Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations

Histochemical Journal

Volumn 33, Issue 4, 2001, Pages 193-200

  Semczuk, Andrzej ^a   Skomra, Danuta ^a   Cybulski, Marek ^a   Jakowicki, Jerzy A ^a  

^a Lublin University   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NUCLEAR; CODON; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR PROTEINS; POINT MUTATION; PROGNOSIS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034871480     PISSN: 00182214     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1017996506357     Document Type: Article

References (48)

1. Perspective: Defects in cell cycle control and cancer
2. Monoclonal antibody Ki-67: Its use in histopathology
3. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium
4. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
5. Alteration of the p53 tumour suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado
6. Endometrial carcinoma: Immunohistochemically detected proliferation index as a prognosticator of long-term outcome
7. Proliferation index determined by MIB-1 and recurrence in endometrial cancer
8. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer
9. MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up
10. Cell cycle analysis of a cell-associated human nuclear antigen defined by the monoclonal antibody Ki-67
11. HER-2/neu expression: A major prognostic factor in endometrial cancer
12. MIB-1 labelling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix
13. Molecular events in endometrial carcinogenesis
14. Nonparametric estimation from incomplete observations
15. New Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 bases repetitive elements encoding for the Ki-67 epitop
16. Markers of proliferation and morpho-immunologic parameters in evaluation of prognostic factors in endometrial tumours
17. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer
18. Correlation between histological grading and growth-related factors in human endometrial adenocarcinomas
19. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis
20. Pretreatment assessment of prognostic indicators in endometrial cancer
21. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1
22. Optimizing immunohistochemistry: Antigen retrieval and signal amplification. Review
23. Cell cycle regulators: Mechanisms and their role in aetiology, prognosis, and treatment of cancer
24. Clinical implications of K-ras mutations in malignant epithelial tumours of the endometrium
25. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression
26. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki-67 proliferation marker in normal, hyperplastic, and malignant endometrium
27. Prognostic and therapeutic implications of the MIB-1 labeling index in breast cancer
28. Expression of MIB-I (paraffin Ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type
29. p53 overexpression and mutation in endometrial carcinoma: Inverted relation with estrogen and progesterone receptor status
30. A comparison of proliferative markers and their prognostic value for women with endometrial carcinoma
31. MIB-1 as a prognostic marker in transitional cell carcinoma of the bladder: Clinical significance and comparison with other prognostic factors
32. The epidemiology of endometrial cancer
33. PTEN mutation in endometrial cancers is associated with favourable clinical and pathologic characteristics
34. HER-2/neu amplification and overexpression in endometrial carcinoma
35. Endometrial carcinoma
36. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas
37. Telomeric lengths and telomerase activity in liposarcomas
38. The Ki-67 protein: From the known and the unknown
39. Detection of K-ras mutations in cancerous lesions of human endometrium
40. K-ras gene point mutations in human endometrial carcinomas: Correlation with clinicopathological features and patients' outcome
41. RB protein expression in human endometrial carcinomas - An immunohistochemical study
42. Theories of endometrial carcinogenesis: A multidisciplinary approach
43. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma
44. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
45. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: Correlation with Ki67 index